In Re: Humira (Adalimumab) Antitrust Litigation

  1. July 30, 2020

    Humira Buyers Take AbbVie Antitrust Challenge To 7th Circ.

    Humira buyers are appealing to the Seventh Circuit an Illinois federal judge's dismissal of their proposed class action claiming AbbVie Inc. built a "patent thicket" around the immunosuppressant drug to block cheaper biosimilars from entering the market.

  2. June 12, 2020

    4 Takeaways As AbbVie Crushes 'Patent Thicket' Litigation

    AbbVie's rapid and resounding defeat of high-profile antitrust litigation targeting a "patent thicket" guarding Humira, the world's best-selling drug, will help Big Pharma plant dense new jungles of intellectual property to block biosimilar makers that are already struggling to penetrate the lucrative biologics sector. Here are four takeaways to know.

  3. June 08, 2020

    AbbVie Beats Antitrust Challenge To Humira 'Patent Thicket'

    Humira buyers have alleged neither an antitrust violation nor an antitrust injury in their novel lawsuit claiming AbbVie built a "patent thicket" around its immunosuppressant drug Humira to block cheaper biosimilars from coming onto the market, an Illinois federal judge ruled Monday.

  4. May 20, 2020

    AbbVie Says Recent Antitrust Ruling Irrelevant In Humira Case

    AbbVie Inc. has told an Illinois federal court that a recent ruling in a case involving speech recognition technology is not relevant whatsoever to Humira buyers' allegations that the pharmaceutical giant used a "patent thicket" to illegally delay less-expensive biosimilars for the immunosuppressant.

  5. November 25, 2019

    Humira Buyers Say They've Proven AbbVie's 'Patent Thicket'

    AbbVie shouldn't be able to escape first-of-its-kind litigation accusing the pharmaceutical giant of building a "patent thicket" around its immunosuppressant Humira in order to block cheaper biosimilars from coming onto the market, Humira buyers have told an Illinois federal judge.

  6. October 15, 2019

    AbbVie Says Humira's Many Patents Is No Antitrust Violation

    AbbVie and several other drugmakers have asked an Illinois federal court to dismiss a sweeping proposed class action accusing the company of illegally shielding its immunosuppressant Humira from competition with a "patent thicket," saying there is no limit to how many patents a company can hold.

  7. June 25, 2019

    Big Pharma's Biggest New Cases Of 2019: Midyear Report

    Multibillion-dollar lawsuits targeting major drugmakers emerged with astonishing frequency during the first half of 2019, threatening civil and criminal liability for all manner of alleged wheeling and dealing. Here, Law360 highlights the latest developments and upcoming action in the pharmaceutical world's hottest new cases.

  8. June 07, 2019

    Meet The Top Attys In AbbVie's Antitrust Battle Royal

    Powerhouse plaintiffs lawyers and BigLaw brawlers are set for a rowdy antitrust battle over AbbVie’s alleged scheme to protect the market for its immunosuppressant Humira, the world’s best-selling drug, by cultivating an impenetrable “patent thicket” and engaging in devious horse-trading with biosimilar makers. Here, Law360 looks at the top attorneys who will shape the case's fate. 

  9. March 27, 2019

    'Groundbreaking' AbbVie Suits Test Bold Anti-Generic Tactics

    A trio of trailblazing antitrust lawsuits targeting AbbVie Inc. will force a day of reckoning for some of Big Pharma's most audacious and controversial maneuvers to delay generic and biosimilar competition, experts say.

  10. March 18, 2019

    AbbVie Faces 1st Antitrust Suit Over Humira 'Patent Thicket'

    AbbVie Inc.'s colossal "patent thicket" for its $20-billion-per-year immunosuppressant Humira has empowered it to block less-expensive biosimilars in violation of numerous antitrust laws, according to a first-of-its-kind suit launched Monday.